Pitfalls of FDA-approved germline cancer predisposition tests
“The FDA approval on September 29, 2023, for ‘class III de novo’ blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct to Consumer (DTC) path.”
BUFFALO, NY – December 30, 2024 – A new editorial was published in Oncotarget’s Volume 15 on December 24, 2024, titled “Pitfalls and perils from FDA-approved germ-line cancer predisposition tests.“
Authored by Dr. Wafik S. El-Deiry, Editor-in-Chief of Oncotarget, and Dr. Eli Y. Adashi from Brown University, the article highlights concerns about the risks ...




